We are live on
!
Find out more
NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
-20.14%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$243M
AUM Growth
-$279M
(-54%)
Cap. Flow
-$206M
Cap. Flow
% of AUM
-85.09%
Top 10 Holdings %
Top 10 Hldgs %
82.71%
Holding
61
New
5
Increased
9
Reduced
8
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$27.5M |
| 2 |
Heron Therapeutics
HRTX
|
+$20.1M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$7.77M |
| 4 |
Insmed
INSM
|
+$5.98M |
| 5 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$5.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$30.2M |
| 2 |
Viatris
VTRS
|
+$25.5M |
| 3 |
Exelixis
EXEL
|
+$25.4M |
| 4 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$21.5M |
| 5 |
TVRD
Tvardi Therapeutics
TVRD
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
| $35.8M | 14.76% |
499,200
-500,800
| -50% | -$40.3M |
|
2
CALL
BioMarin Pharmaceuticals
BMRN
$11.4B
| $29.1M | 11.98% |
341,400
+41,400
| +14% | +$3.94M |
|
|
3
Novartis
NVS
$297B
| $27.1M | 11.18% |
+352,787
| New | +$27.5M |
|
4
CALL
Teva Pharmaceuticals
TEVA
$36.3B
| $26M | 10.7% |
+1,683,500
| New | +$34.5M |
|
|
5
Heron Therapeutics
HRTX
$86.9M
| $21.2M | 8.76% |
819,164
+729,315
| +812% | +$20.1M |
|
|
BOLD
6
DELISTED
Audentes Therapeutics, Inc
BOLD
| $16.3M | 6.72% |
764,193
+223,021
| +41% | +$5.75M |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $12.8M | 5.26% |
894,679
-503,898
| -36% | -$10M |
|
8
Bausch Health
BHC
$1.66B
| $12.3M | 5.06% |
664,837
+119,337
| +22% | +$2.84M |
|
|
9
Insmed
INSM
$23.3B
| $11M | 4.54% |
838,946
+374,787
| +81% | +$5.98M |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.1M | 3.75% |
221,662
-327,569
| -60% | -$12.3M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.74M | 3.19% |
+396,198
| New | +$7.77M |
|
|
STML
12
DELISTED
Stemline Therapeutics, Inc.
STML
| $6.76M | 2.79% |
711,558
+129,488
| +22% | +$1.68M |
|
|
13
Exelixis
EXEL
$14B
| $6.05M | 2.49% |
307,739
-1,427,291
| -82% | -$25.4M |
|
|
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
| $5.63M | 2.32% |
714,764
-193,900
| -21% | -$1.85M |
|
|
CHMA
15
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $3.32M | 1.37% |
1,066,439
+429,793
| +68% | +$1.54M |
|
16
Gyre Therapeutics
GYRE
$670M
| $2.97M | 1.22% |
50,135
-68,876
| -58% | -$5.08M |
|
|
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $2.56M | 1.05% |
121,892
+91,270
| +298% | +$2.24M |
|
18
Sutro Biopharma
STRO
$391M
| $2.25M | 0.93% |
24,950
+1,789
| +8% | +$216K |
|
|
ZSAN
19
DELISTED
Zosano Pharma Corporation
ZSAN
| $1.69M | 0.7% |
22,821
-6,715
| -23% | -$850K |
|
|
ATNX
20
DELISTED
Athenex, Inc. Common Stock
ATNX
| $1.56M | 0.65% |
+6,165
| New | +$1.57M |
|
|
RVLP
21
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $935K | 0.39% |
+120,620
| New | +$965K |
|
22
MediWound
MDWD
$183M
| $424K | 0.17% |
14,935
-9,790
| -40% | -$380K |
|
|
VCNX
23
DELISTED
Vaccinex, Inc. Common Stock
VCNX
| $62K | 0.03% |
81
| – | – |
|
24
Abeona Therapeutics
ABEO
$364M
| – | – |
-33,999
| Closed | -$10.9M |
|
25
CALL
Acadia Pharmaceuticals
ACAD
$4.25B
| – | – |
-500,000
| Closed | -$10.4M |
|
Similar funds
KAM
VCP
PFC
FCA
TA
EBIM
BCM
ACP
Nexthera Capital's Q4 2018 Portfolio in Review
As of Q4 2018, Nexthera Capital held 61 positions worth $243M, down 54% from $522M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Nexthera Capital withdrew a net $206M in Q4 2018, closing 38 positions and reducing 8 holdings. Its most notable exit was Allergan plc, an estimated $30.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 65% a quarter earlier.
Against the trend, Nexthera Capital opened a new position in Novartis worth $27.1M.
- Nexthera Capital's largest Q4 2018 buy was Novartis: 352,787 shares worth $27.1M.
- Nexthera Capital added most to Heron Therapeutics in Q4 2018, an estimated $20.1M increase.
- Nexthera Capital's biggest Q4 2018 reduction was Exelixis, cutting an estimated $25.4M.
- Nexthera Capital fully exited Allergan plc in Q4 2018, selling an estimated $30.2M.
- Nexthera Capital's ten largest holdings make up 83% of its $243M portfolio in Q4 2018.
- Nexthera Capital opened 5 new positions and closed 38 in Q4 2018.
- Nexthera Capital's portfolio value fell 54% quarter-over-quarter to $243M.
Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.